Kuva Labs Launches $5.00/Share Tender Offer for Lisata Therapeutics (LSTA) Plus $1.00 CVR

♦ Key Takeaways

⚠ UPDATE (April 15, 2026): The deal is in serious jeopardy — Kuva Labs has missed two tender-offer commencement deadlines (April 3 and April 13) and is seeking alternative financing. Lisata now warns there is "no assurance" the offer will launch. LSTA now trades at $2.92 vs. the $5.00 cash offer. Read the Amendments & Updates section below for full analysis.
Kuva Labs is acquiring Lisata Therapeutics (NASDAQ: LSTA) for $5.00 per share in cash plus a contingent value right worth up to $1.00 if a certepetide NDA is filed within seven years.
LSTA trades at $5.01, essentially at the cash offer price — the market is assigning near-zero value to the CVR and pricing in minimal deal risk.
No financing condition, board unanimously recommends tendering, and a second-step merger sweeps up any untendered shares at the same price.
The tender offer has not yet formally commenced — the SC14D9C filed March 9, 2026 is a preliminary communication. Watch for the Schedule TO to set the actual expiration date.

The Offer

Kuva Labs, Inc., a privately held company, has entered into a definitive agreement to acquire Lisata Therapeutics, Inc. (NASDAQ: LSTA) through an all-cash tender offer at $5.00 per share plus one contingent value right per share. Lisata is a clinical-stage pharmaceutical company developing certepetide for the treatment of advanced solid tumors. The definitive agreement was announced on March 6, 2026, upgrading an earlier term sheet from January that had proposed $4.00 per share plus two CVRs.

Lisata's board of directors unanimously approved the deal and recommends that all stockholders accept the offer and tender their shares. Following the tender, Kuva will acquire any remaining untendered shares through a second-step merger at the same consideration — so this is a 100% buyout, not a partial offer. The transaction is expected to close in Q2 2026, after which Lisata will delist from Nasdaq and cease SEC reporting.

Why This Is Interesting

At first glance, the numbers here don't scream opportunity. LSTA closed at $5.01, which is a penny above the $5.00 cash offer price — meaning there's effectively no spread on the cash portion. The market is treating the CVR as essentially worthless and pricing the deal as a near-certainty to close. For investors looking for a quick arbitrage play, there's no free money sitting on the table right now.

The more interesting question is whether the CVR has any real value. Certepetide is Lisata's lead asset, a peptide designed to enhance tumor penetration of chemotherapy agents. The CVR pays $1.00 per share if an NDA or equivalent regulatory filing is made for certepetide anywhere in the world within seven years of closing. That's a long runway, but certepetide is still in clinical development — an NDA is not imminent. On the original January 2026 term sheet, Kuva had offered two CVRs (one tied to the China rights reverting from Qilu Pharmaceutical, one tied to an NDA filing), each worth $1.00. The definitive agreement consolidated that into a single CVR and bumped the cash component by a dollar. That restructuring suggests Kuva wanted to simplify the contingent payouts — and possibly that the Qilu-related milestone was deemed unlikely enough to drop.

Key Terms

Offer price: $5.00 per share in cash at closing, plus one CVR per share
CVR details: Pays $1.00 per share if an NDA or similar regulatory filing for certepetide is filed or accepted by the FDA or any governmental authority worldwide, prior to the seventh anniversary of closing
CVR tradability: The original term sheet described the CVRs as non-tradeable. If that carries through to the definitive agreement, holders will have no liquidity on the CVR — you're locked in for up to seven years with no way to sell
Minimum tender condition: A majority of outstanding shares must be validly tendered
Financing condition: None — the merger agreement explicitly excludes a financing condition
Second-step merger: Kuva will acquire untendered shares and convertible securities through a back-end merger at the same $5.00 plus CVR consideration
Board recommendation: Unanimous approval and recommendation to tender
Legal advisors: Mintz Levin (Lisata), Goodwin Procter (Kuva); H.C. Wainwright served as Lisata's financial advisor

Timeline

January 21, 2026

Lisata and Kuva Labs announce binding term sheet at $4.00/share plus two CVRs.

March 6, 2026

Definitive merger agreement signed. Price restructured to $5.00 cash plus one CVR.

March 9, 2026

SC14D9C preliminary communication filed with the SEC, along with an 8-K referencing the definitive agreement.

TBD

Schedule TO filing expected — this will formally commence the tender offer and set the expiration date (typically 20 business days after commencement).

Q2 2026 (expected)

Transaction expected to close, followed by second-step merger, Nasdaq delisting, and SEC deregistration.

Risks

No spread to capture. With LSTA trading at $5.01 against a $5.00 cash offer, there's no arbitrage profit on the cash component. Anyone buying here is paying a penny more than the offer price and betting entirely on CVR value or a competing bid.
CVR is speculative and likely illiquid. Certepetide is still in clinical trials. An NDA filing within seven years is possible but far from certain, and if the CVR is non-tradeable (as indicated in the term sheet), you can't exit the position. The market's near-zero implied CVR value tells you what arb desks think of the odds.
Privately held acquirer. Kuva Labs is not a public company, which limits the information available about its financial capacity. The absence of a financing condition provides some comfort, but there's less transparency than in a deal with a public acquirer.
Offer not yet commenced. The SC14D9C is a preliminary communication only. The formal Schedule TO has not been filed, meaning the expiration date, withdrawal rights period, and detailed offer conditions are not yet set. Terms could still shift before commencement.
Minimum tender condition. A majority of outstanding shares must be tendered. If Lisata's shareholder base is fragmented or disengaged, meeting this threshold could require extensions — though the unanimous board recommendation should help drive participation.

This analysis is for informational purposes only and does not constitute investment advice. Read the complete filing and consult your own advisors before making any decisions.

Amendment: Kuva Labs Financing Delays Put the LSTA Deal at Serious Risk

Filed April 15, 2026 | SC14D9C

The Kuva Labs tender offer for Lisata Therapeutics (LSTA) has not commenced — and Lisata now openly warns there is no assurance it ever will. LSTA has collapsed from $5.01 to $2.92, a 42% discount to the $5.00 cash offer, as the market re-prices the probability that this deal actually closes.

What Changed

Tender offer still not launched. Under the merger agreement, Kuva was obligated to commence the tender offer by April 3, 2026. On April 2, the parties signed a waiver pushing the deadline to April 13, 2026. April 13 came and went. The April 15 filing confirms the offer has still not been commenced.
Buyer is hunting for new financing. Kuva has told Lisata it is "seeking alternative sources of financing on terms more favorable to Parent to fund the tender offer." Translation: Kuva's original financing fell through or became uneconomic. The agreement never had a financing condition, but it turns out that protection only matters if the buyer has the money — and Kuva evidently does not.
Lisata's own language turned cautionary. The filing states there is "no assurance" the tender offer will commence at all, and flags potential termination of the merger agreement. This is a meaningful shift from the "expected to close in Q2 2026" framing in the March 6 announcement.
Termination fee is small. If either side walks, the termination fee is $2 million — a rounding error on a roughly $37 million deal. That asymmetry does not give Kuva much incentive to push through an unfavorable financing package.

Impact Assessment

This is no longer a no-spread arbitrage — it is a binary event. At $2.92, the market is pricing roughly a 40% probability the deal closes at $5.00, assuming an unaffected downside near the $1.86 52-week low. Upside is a clean 71% to the cash price if Kuva secures financing and commences the offer; downside is a drop back toward pre-deal levels if the merger agreement terminates.

The tell is that Kuva is still talking. A buyer walking away typically walks — Kuva instead asked for a waiver and is actively "discussing financing and timing" with Lisata. That is more consistent with a buyer trying to save the deal than one trying to exit. But private acquirers without committed financing are exactly the risk profile where tender offers fall apart, and the CVR upside — which was already priced at near zero — is now entirely beside the point. The question is whether the $5.00 cash ever arrives.

Updated Key Facts

Detail	Previous	Updated
Tender offer status	Preliminary SC14D9C filed; Schedule TO expected	Offer still not commenced; Kuva seeking alternative financing
Tender offer commencement deadline	April 3, 2026	Extended to April 13, 2026 (waiver signed April 2); deadline passed
Deal completion risk	Minimal (priced at near-certainty)	Material — "no assurance" offer will commence
Current stock price	$5.01	$2.92
Termination fee	Not highlighted	$2 million payable by either side
Expected close	Q2 2026	Q2 2026 targeted, but contingent on Kuva securing financing